Degeneration Clinical Trials

294 recruitingLast updated: July 25, 2026

There are 294 actively recruiting degeneration clinical trials across 52 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Dallas, Texas, United States, Boston, Massachusetts, United States, Austin, Texas, United States. Updated daily from ClinicalTrials.gov.


Degeneration Trials at a Glance

294 actively recruiting trials for degeneration are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 86 trials, with the heaviest enrollment activity in Dallas, Boston, and Austin. Lead sponsors running degeneration studies include National Eye Institute (NEI), Medical University of Vienna, and Hoffmann-La Roche.

Browse degeneration trials by phase

Treatments under study

About Degeneration Clinical Trials

Looking for clinical trials for Degeneration? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 294 trials

Recruiting
Not Applicable

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

Complex Congenital Heart DefectDysfunctional RVOT ConduitPulmonary Valve Insufficiency+1 more
Edwards Lifesciences108 enrolled27 locationsNCT02744677
Recruiting
Not Applicable

Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)
National Taiwan University Hospital1,000 enrolled1 locationNCT06843499
Recruiting
Not Applicable

Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)
National Taiwan University Hospital4,300 enrolled1 locationNCT07069647
Recruiting
Not Applicable

Effects of Goji vs. Fiber on Macular Degeneration

Age-Related Macular Degeneration
University of California, Davis60 enrolled1 locationNCT06237127
Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting
Phase 2

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Age related macular degeneration (AMD)Geographic Atrophy (GA)
ONL Therapeutics324 enrolled53 locationsNCT06659445
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT07482176
Recruiting

Imaging Studies in Corticobasal Syndrome

Corticobasal SyndromeCorticobasal Syndrome(CBS)Corticobasal Degeneration+2 more
Jennifer Whitwell80 enrolled1 locationNCT07000851
Recruiting
Phase 1Phase 2

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic AtrophyAge-Related Macular Degeneration
AbbVie66 enrolled5 locationsNCT07160179
Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled13 locationsNCT07144137
Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled52 locationsNCT04853251
Recruiting
Phase 1

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Long COVIDSARS CoV-2Neurodegeneration+1 more
Stephanie B. Seminara, MD40 enrolled1 locationNCT07224490
Recruiting
Phase 2Phase 3

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled87 locationsNCT07440225
Recruiting
Phase 2Phase 3

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled56 locationsNCT07496567
Recruiting
Phase 3

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular DegenerationnAMD
Amgen304 enrolled29 locationsNCT07614776
Recruiting
Phase 1

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Cone-Rod DegenerationRod-Cone Degeneration
National Eye Institute (NEI)165 enrolled2 locationsNCT04289571
Recruiting
Phase 3

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled218 locationsNCT06541704
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled51 locationsNCT07441642
Recruiting
Not Applicable

Visual Remapping to Aid Reading With Field Loss

Age-Related Macular Degeneration
University of Minnesota108 enrolled1 locationNCT03848663
Recruiting
Phase 1Phase 2

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Neovascular (Wet) Age-related Macular Degeneration
Eyconis INC.30 enrolled6 locationsNCT07587515